DavidRizzieriMDCPE

PubMed

• Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
  Abid, M. B., Hemant S Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V Michelis, Taiga Nishihori, Mrinal Pat...> ;Blood Advances. 2023 Nov 28
• 1 citations
  Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML withgene overexpression.
  Eytan M Stein, Stephane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L Liesveld, Rachel J Cook, Philippe Rousselot, David A Rizzieri, Thorsten Braun, Gail J Roboz, ...> ;Leukemia & Lymphoma. 2023 Dec 1
• 2 citations
  A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis.
  Roni Tamari, Donal P McLornan, Kwang Woo Ahn, Noel Estrada-Merly, Juan Carlos Hernández-Boluda, Sergio Giralt, Jeanne Palmer, Robert Peter Gale, Zachariah DeFilipp, Da...> ;Blood Advances. 2023 Aug 8
• 9 citations
  Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
  Guru Subramanian Guru Murthy, Soyoung Kim, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Amer Assal, Talha Badar, Sherif M Badawy, Karen Ballen, Amer Beitin...> ;Haematologica. 2023 Jul 1
• Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
  Chenyu Lin, Ahmed Galal, David Rizzieri, Sant Chawla, Seung T Lee, Angela Georgy, Kristina Dabovic, Thomas Strack, Matthew McKinney> ;Cancer Investigation. 2023 Jan 31
• 5 citations
  An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.
  Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres, Bruno C Medeiros, Eunice S Wang, Paul J Shami, Kehinde Adekola, Selina Luger, Maria R...> ;Blood. 2023 Jan 19
• 12 citations
  Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML.
  Stéphane de Botton, Thomas Cluzeau, Carlos Vigil, Rachel J Cook, Philippe Rousselot, David A Rizzieri, Jane L Liesveld, Pierre Fenaux, Thorsten Braun, Anne Banos, Jose...> ;Blood Advances. 2023 May 9
• 12 citations
  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
• 1 citations
  Revisiting a single day salvage conditioning following graft failure.
  Emmanuel Katsanis, Therese Hennig, Jacob E Robinson, Gwynn Long, Nelson Chao, Mitchell Horwitz, David Rizzieri> ;Bone Marrow Transplantation. 2022 Dec 1
• 14 citations
  Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
  Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, Eunice S Wang, David A Rizzieri, Sumithira Vasu, Todd L Rosenblat, Christopher L Brooks, Nassir Habboubi, Tariq I Mu...> ;Journal of Clinical Oncology. 2022 Sep 10
• Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
  Andrew M Strand, Barbara D Alexander, Eric Sarpong, Jessica Retuerto Wong, Ashley Engemann, David Rizzieri, Yuan Wu, Melissa D Johnson> ;Mycoses. 2022 Nov 1
• 57 citations
  Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
  Daniel A Pollyea, Courtney D DiNardo, Martha L Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A Rizzieri, B Douglas Smith, Atsushi Shinagawa, Robert...> ;Clinical Cancer Research. 2022 Jul 1
• 3 citations
  Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  James A Davis, David A Rizzieri, Andrew A Lane, Justin Taylor, Muhammad Salman Faisal, Sumithira Vasu, Deborah Soong, Hong Li, Amanda Herbst, I Brian Greenwell> ;Leukemia & Lymphoma. 2022 Nov 1
• 9 citations
  The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Tra...
  Matthew Mei, Raju Pillai, Soyoung Kim, Noel Estrada-Merly, Michelle Afkhami, Lixin Yang, Zhuo Meng, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Amer Beitinjane...> ;Haematologica. 2023 Jan 1
• 3 citations
  Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow...
  Hemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, Hassan B Alkhateeb, Susan Bal, Mohamed A Kharfan-Dabaja, Bhagirathbhai Dholaria, Francine Foss, Lohith Gowda, Deepa...> ;Transplantation and Cellular Therapy. 2022 Apr 1
• 31 citations
  Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors...
  Guru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, Noel Estrada-Merly, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Sherif M Badawy, Amer Beitinjaneh, Chr...> ;JAMA Oncology. 2022 Mar 1
• 2 citations
  CVD Risk Factors in the Ukrainian Roma and Meta-Analysis of Their Prevalence in Roma Populations Worldwide.
  Matea Zajc Petranović, Ashley Elizabeth Rizzieri, Dharshan Sivaraj, Nina Smolej Narančić, Tatjana Škarić-Jurić, Željka Celinšćak, Anita Stojanović Marković, Marijana P...> ;Journal of Personalized Medicine. 2021 Nov 2
• 2 citations
  Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation.
  Patrick Smith, Meagan Lew, Yen P. Lowder, Kristi Romero, Jillian C. Thompson, Lauren Bohannon, Alyssa Pittman, Alexandra Artica, Sendhilnathan Ramalingam, Taewoong Cho...> ;Bone Marrow Transplantation. 2021 Oct 19
• 4 citations
  Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
  Prioty Islam, David A. Rizzieri, Chenyu Lin, Carlos M. de Castro, Louis F. Diehl, Zhiguo Li, Joseph O. Moore, Tod A. Morris, Anne W. Beaven> ;Cancer Investigation. 2021 Oct 13
• 5 citations
  Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
  Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, Mei-Jie Zhang, Khalid Bo-Subait, Jonathan Sanchez, Hai-Lin Wang, Mahmoud Aljurf, Amer Assal, Ulrik...> ;Blood Advances. 2021 Sep 22
• 33 citations
  Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
  Matthew J Wieduwilt, Leland Metheny, Mei-Jie Zhang, Hai-Lin Wang, Noel Estrada-Merly, David I. Marks, A Samar Al-Homsi, Lori Muffly, Nelson J. Chao, David A. Rizzieri,...> ;Blood Advances. 2021 Sep 21
• 4 citations
  Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid M...
  Nina Orfali, Mei-Jie Zhang, Mariam Allbee-Johnson, Jaap Jan Boelens, Andrew S. Artz, Claudio G. Brunstein, Ian K. McNiece, Filippo Milano, Muhammad Bilal Abid, Lynette...> ;Transplantation and Cellular Therapy. 2021 Sep 7
• 4 citations
  Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)
  Hagop M. Kantarjian, Kebede H. Begna, Jessica K. Altman, Stuart L. Goldberg, Mikkael A. Sekeres, Stephen A. Strickland, Martha Arellano, David F. Claxton, Maria R. Bae...> ;Cancer. 2021 Aug 23
• 9 citations
  Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
  Leland Metheny, Natalie S. Callander, Aric C. Hall, Mei-Jei Zhang, Khalid Bo-Subait, Hai-Lin Wang, Vaibhav Agrawal, A. Samer Al-Homsi, Amer Assal, Ulrike Bacher, Amer ...> ;Transplantation and Cellular Therapy. 2021 Nov 1
• 9 citations
  Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
  Betul Oran, Kwang Woo Ahn, Caitrin Fretham, Amer Beitinjaneh, Asad Bashey, Attaphol Pawarode, Baldeep Wirk, Bart L. Scott, Bipin N. Savani, Christopher Bredeson, Danie...> ;Transplantation and Cellular Therapy. 2021 Aug 14
• Join now to see all

Journal Articles

• MDS: unraveling the mystery  
  Rizzieri DA, Blood, 12/1/2013
• The genetic landscape of mutations in Burkitt lymphoma  
  Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, ..., Nat Genet, 11/1/2012
• Phase II Study of Cenersen, an Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab for High Risk CLL  
  Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, Decastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D, Leuk Lymphoma, 2/1/2012
• Elacytarabine,a novel 5’-claidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia  
  Giles F, Rizzieri D, Ravandi F, Swords R, Jacobsen TF, O'Brien S, Leuk Res, 1/1/2012
• Leukemic Stem Cells, A Review  
  Jenny O’Brien, David Rizzieri, Cancer Investigation, 1/1/2012
• MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia  
  Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA, Talpaz M, Clark J, Watson P, Xiao A, Zhao B, Bergstrom D, Le Coutre PD, Freedman SJ, Cortes JE, Leukemia, 1/1/2012
• Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia  
  O'Brien S, Rizzieri DA, Vey N, Ravandi F, Krug UO, Sekeres MA, Dennis M, Venditti A, Berry DA, Jacobsen TF, Staudacher K, Bergeland T, Giles FJ, Br J Haematol, 1/1/2012
• Chemoimmunotherapy’s potential to impact paroxysmal nocturnal hemoglobinuria  
  Rizzieri DA, Walsh K, Clin Adv Hematol Oncol, 1/1/2012
• Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning  
  Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME, Biol Blood Marrow Transplant, 6/1/2011
• Early Pre/Post Transplant Fluoro-Deoxyglucose Positive Emission Tomography (FDG-PET) does predict outcome for patients undergoing hematopoietic stem cell transplantati...  
  J. Palmer, T. Goggins, G. Broadwater, N.Chao, G. Long, M. Horwitz, A. Beavens, J. Chute, K. Sullivan, C. Gasparetto, E. Coleman, D. Rizzieri, Bil Blood and Marrow Trns, 1/1/2011
• Renal Shielding and Dosimetry for Patients with Severe Systemic Sclerosis Receiving Immunoablation with Total Body Irradiation in the Scleroderma: Cyclophosphamide or ...  
  Craciunescu OI, Steffey BA, Kelsey CR, Larrier NA, Paarz-Largay CJ, Prosnitz RG, Chao N, Chute J, Gasparetto C, Horwitz M, Long G, Rizzieri D, Sullivan KM, Int J Radiat Oncol Biol Phys, 1/1/2011
• Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a compreh...  
  Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rehder C, Lagoo A, Horwitz M, Rizzieri D, Yu J, Goodman B, Datto M, Buckley P, Am J Clin Pathol, 1/1/2011
• Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL)  
  Advani AS, Gibson S, Douglas E, Diacovo J, Elson P, Kalaycio M, Copelan E, Sekeres M, Sobecks R, Sungren S, Lagoo A, Rizzieri D, Hsi E, Br J Haematol, 1/1/2011
• Alemtuzumab for the prevention and treatment of graft-versus-host disease  
  Kanda J, Lopez RD, Rizzieri DA, Int J Hematol, 1/1/2011
• Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismat...  
  Rizzieri DA, Crout C, Storms R, Golob J, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Lagoo AS, Morris A, Beaven A, Yang Y, Peterson B, Li Z, Chao NJ, Cancer Invest, 1/1/2011
• Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors  
  Kelsey CR, Horwitz ME, Chino JP, Craciunescu O, Steffey B, Folz RJ, Chao NJ, Rizzieri DA, Marks LB, Int J Radiat Oncol Biol Phys, 1/1/2011
• Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia  
  Rizzieri D, LoRusso S, Tse W, Khan K, Advani A, Moore J, Karsten V, Cahill A, Gerson SL, Clin Lymphoma Myeloma Leuk, 6/1/2010
• Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose Dense and Intense Therapy  
  Christopher A. Crout, Liang-Piu Koh, Jon P. Gockerman, Joseph O. Moore, Carlos DeCastro, Gwynn D. Long, Louis Diehl, Christina Gasparetto, Donna Niedzwiecki, Jon Edwar..., Cancer Invest, 1/1/2010
• Comparable survival after hla-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogeneti...  
  Vikas Gupta, Martin S Tallman, Wensheng He, Brent R Logan, Edward A Copelan, Robert Peter Gale, Hanna J. Khoury, Thomas Klumpp, John Koreth, Hillard M Lazarus, David I..., Blood, 1/1/2010
• Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure  
  Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Sc..., J Clin Oncol, 1/1/2010
• Haploidentical transplantation for leukemia  
  Kanda J, Chao NJ, Rizzieri DA, Curr Oncol Rep, 1/1/2010
• Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors  
  Rizzieri DA, Dev P, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Chao NJ, Bone Marrow Transplant, 1/1/2009
• Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia  
  Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, Kwon HY, Kim J, Chute JP, Rizzieri D, Munchhof M, Vanarsdale T, Beachy PA, Reya T, Nature, 1/1/2009
• Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia  
  Rizzieri DA, O'Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO, Cancer, 1/1/2009
• Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients  
  Horwitz ME, Morris A, Gasparetto C, Sullivan K, Long G, Chute J, Rizzieri D, McPherson J, Chao N, Biol Blood Marrow Transplant, 1/1/2008
• Join now to see all

Abstracts/Posters

• Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Daily Chlorhexidine Gluconate Bathing Reduces the Rate of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Stem Cell Transplantation
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Geriatric Assessment Identifies Impairments in Younger Candidates for Allogeneic Hematopoietic Stem Cell Transplantation
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Decreased Mortality after the First Year of Allogeneic Hematopoietic Stem Cell Transplant in Recipients of Umbilical Cord Blood Vs. Matched Related or Matched Unrelate...
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
  David A. Rizzieri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• ET190L1-ARTEMISTM T Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Ce... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all